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Abstract
Background: The 5-year overall survival rates for head and neck cancer (HNC) relies on distant metastasis.
Importantly, the epithelial-mesenchymal transition (EMT) is believed to be an initial step of metastasis. However, the
relationship of epigenetic with EMT formation is still unexplored in HNC. This study focuses on invasive subclones
of HNC cell lines through the simulation of invasion in vitro; and underlying mechanisms were analyzed including
DNA methylation and gene expression profile.
Methods: Invasive subclones of NHC cell lines were successfully obtained using transwell coated with Matrixgel.
Cells invaded through 8 μm pore several times were subcultured and examined with EMT features including
morphology, EMT marker genes expression, and invasive ability. Moreover, compared the profile of genes
expression in parental and invasive cells was analyzed using mRNA expression array.
Results: DNA methyltransferase 3B (DNMT 3B) was upregulated in invasive subclones and might control the
5′ region of E-cadherin (E-cad) methylation and further inhibited E-cad protein expression. Interference of DNMT
3B by siRNA or miRNA 29b could reduce EMT and cell invasion. Expression array analysis revealed the most possible
involved pathways in cell invasion including arginine and proline metabolism, TGF-beta, and focal adhesion.
Conclusions: DNMT 3B might control EMT by DNA methylation manner in invasive HNC cell lines. Moreover,
miR-29b mimic downregulated DNMT 3B and inhibited EMT and cell invasion indicated the role of therapeutic
agent for invasive HNC. Genes identified from array data and new molecules are involved in metastasis of HNC
need further validation.
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Background
Head and neck cancer (HNC) is defined as a tumor that
develops from mucosal linings of upper aerodigestive
tract including the nasopharynx, oral cavity, oropharynx,
hypopharynx, and larynx. HNC is the sixth common
cancer worldwide [1] and more than 600,000 cases of
HNC are reported annually [2]. The major risk factors of
HNC are tobacco smoking [3], alcohol consumption [4],
chewing of betel quid [5], and human papillomavirus
infection [6]. The 5-year overall survival rates for HNC
are approximately 50 % but decline to 10 % when metas-
tasis is diagnosed [7, 8]. Hence, the comprehension of
the underlying mechanism of HNC metastasis is crucial
for therapy and diagnosis of HNC.
Metastasis is believed to consist of four distinct steps
including invasion, intravasation, extravasation, and
colonization [9]. It is suggested that the acquisition of
invasive ability and motility, is the rate-limiting step in
the metastatic cascade [9]. Epithelial-mesenchymal
transition (EMT) was first recognized as a feature of
embryogenesis in the 1980s [10] and involved in many
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critical cellular process such as embryonic morphogen-
esis [11], fibrosis [12], and cancer metastasis [13]. There
is growing evidentiary support that indicates EMT is an
important mechanism for the initial steps of metastasis
[10, 14–16]. EMT is categorized by loss of cell polarity,
gain spindle-shaped morphology, and enhance cell inva-
sion. The numbers of gene expressions are influenced
such as downregulation of epithelia genes including E-
cadherin (E-cad), occluding, claudin, cytokeratin, and
catenin proteins [10]. Loss of E-cad expression is a hall-
mark of EMT [13] and often inversely correlated with
the tumor stage [17]. Additionally, the upregulation of
mesenchymal genes including N-cadherin (N-cad), vimen-
tin, laminin β1 or collagen type VI alpha, as well as various
matrix metalloproteinases (MMPs) [18].
Carcinogenesis is a multistep process involved in the
accumulation of genetic and epigenetic alterations [19].
Epigenetic changes including DNA methylation, histone
modifications, and miRNA-mediated silencing are possibly
reversible. This feature makes them attractive targets for
diagnostic and therapeutic intervention. Hypermethylated
CpG (cytidine-guanosine dinucleotide) islands of tumor
suppressor genes are found as a frequent epigenetic
marker in human carcinomas [20]. DNA methyltrans-
ferases (DNMTs) are enzymes for addition methyl
groups to 5′ carbon of the cytosine ring in CpG site.
There are three DNMTs in mammalian including
DNMT 1, DNMT 3A, and 3B [21]. It is reported that
DNMT 1 is responsible for maintenance of parental
patterns of DNA methylation and DNMT 3A and 3B
establish the new patterns of DNA methylation [22].
The most documented epigenetic control in HNC is the
CpG island promoter hypermethylation-related silencing of
tumor suppressor genes including p16, DAP-K, RAR beta,
MGMT, RASSF1A, and E-cad [23]. These genes are known
to function in the cellular pathways involved in cell cycle
regulatory, apoptosis, DNA repair, and cell mobility [24].
In the present study, the invasive HNSCC cell lines
(A253, RPMI 2650, SCC4, and FaDu) were successfully
subcloned from the cells invaded through Matrigel coated
transwell several times. The features of EMT in invasive
cell lines were assessed including cell morphology and
EMT marker genes expression. Our data showed that
DNMT 3B was upregulated in invasive subclones and
exerted on influence of E-cad methylation. Furthermore,
differential gene expressions of invasive subclone were
explored using an expression array and processed by
DAVID for pathway analysis, which suggests the involve-
ment of possible pathways in cell invasion of HNC.
Methods
Cell lines
HNSCC cell lines: A253 (HTB-41™), RPMI 2650 (CCL-
30™), SCC4 (CRL1624™), and FaDu (HTB-43™) were
obtained from the American Type Culture Collection
(ATCC). For maintenance of all HNSCC cell lines, A253
was cultured in McCoy’s 5a Medium, RPMI 2650 in
Eagle’s Minimum Essential Medium, SCC4 in DMEM/
F12, and FaDu in Minimum Essential Medium, respect-
ively. The cells were cultured in certain medium supple-
mented with 10 % FBS incubated at 37 °C/5 % CO2 atm.
The invasive subclones of HNSCC cell lines were obtained
as previously described in Chu [25] with minor modifica-
tion and were named as the generation of the cell lines
(A253-3, A253-5, RPMI 2650-8, SCC4-4, and FaDu-8).
FE-SEM images
The method of taking FE-SEM image followed our lab
procedure described in Chang [26] with some minor
modifications. In brief, A253-0 and A253-5 (2 × 104)
cells were grown on a sterilized indium-tin-oxide (ITO)
thin-film deposited on an insulating glass for 16 h. Cells
were rinsed, fixed, and dried using a freeze-dry system
(LABCONCO FreeZone 4.5). A field-emission scanning
electron microscope (FE-SEM, JSM-6500, Japan) was
used to examine the cells.
Transfection of siRNA against DNMT 3B
Plasmid (pSUPER) expressing siRNA against DNMT 3B
was obtained from Prof. Show-Li Chen. A stable clone
of A253-5si was achieved by selection of G418 after
transfection with pSUPER-DNMT 3B. MiRNA 29b mimic
was purchased from Ambion (mirVana® miRNA mimic,
MC10103). Transfection reagent RNAi Max (Invitrogen)
was used for transient transfection miRNA 29b according
to the manufacturer’s instructions. Cells transfected with
miRNA 29b mimic were cultured for 48 h and applied to
the subsequent experiments.
E-cadherin promoter methylation analysis
A253 and RPMI 2650 cells were treated with 2 μM of 5-
aza-2′-deoxycytidine (5′AZA) (Sigma, St Louis, MO)-DNA
methyltransferase inhibitors for 4 days and the medium
were replaced every 2 days interval. And then cells were
harvested for analyze the E-cadherin promoter methylation
status with the following methods.
Methylation-specific PCR (MS-PCR) and bisulfite gen-
omic sequencing (BGS) were executed as previously
described [27, 28]. Briefly, genomic DNA was isolated
from cell lines and applied to bisulfite conversion. The
annealing temperature for MS-PCR is 57 °C and for
BGS is 62 °C. The amplicons of MS-PCR were visualized
and photographed on 2 % agarose gel. The amplicons
for BGS were cloned and sequenced. A number of 33
CpG sites were included into BGS analysis. The data
were expressed as percentages of methylated CpG sites
from five clones. The primer sequences for MS-PCR and
BGS of E-cad are listed in Additional file 1: Table S1.
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mRNA and microRNA expression analysis
The methods for analyzing mRNA expression were de-
scribed previously [28]. Briefly, total RNA isolated from
cells was incubated with DNase I and then applied into
reverse transcription (RT) reaction. The quantitative
PCR (Q-PCR) was executed in triplicate and the relative
mRNA expression index was normalized with GADPH
using the comparative Ct method (2-△CT) [29]. The
primer sequences for Q-PCR of gene expression are
listed in Additional file 1: Table S1.
For miRNA 29b, TaqMan® Micro Assay Kit was applied.
Ten nanograms of total RNA were applied into RT reac-
tion using TaqMan® Reverse Transcription Kit according to
the manufacturer’s instructions. The Q-PCR experiment
was performed in triplicate and the relative miRNA 29b
expression index was normalized with the reference
miRNA U6.
Western blot
The analysis of western blot was described previously [28].
Briefly, total protein was extracted and applied to SDS-
polyacrylamide gels for electrophoresis (22 mA per gel).
Protein was transferred onto 0.45 μm polyvinylidene
difluoride (PVDF) membranes for 1.5 h with 400 mA. The
transferred membranes were incubated with blocking
buffers for 10 min and then incubated with specific pri-
mary antibody against E-cadherin (BD), N-cadherin (Gen-
etex), Vimentin (BD), DNMT 1 (Abcam), DNMT 3A
(Abcam), DNMT 3B (Cell signaling), or β-Actin (Cell
signaling) at appropriate dilutions at 4 °C overnight. The
membranes were washed and incubated with horseradish
peroxidase-linked secondary antibody for 1 h at room
temperature. Bands were visualization by chemilumines-
cent reagent and record by photographic film and the
intensity of the band was quantified and calculated. The
results were conducted independently in triplicate.
Migration and invasion assay
Migration assay was conducted with ibidi® culture insert.
Cell was seeded at both side of the insert (35,000 cells in
70 μl medium) and incubated overnight. The insert was
removed next day and photographed at 0 and 48 h. The
gap between cells was quantified with Image J and
presented as percentage of closure compared to 0 h.
The invasion assay was described previously [28].
Briefly, 100 μl of 80 μg Matrixgel (BD) was previously
loaded onto the upper chamber of 24 well transwell (BD,
8 μm pore size) at 37 °C for 2 h and 5 × 104 cells were
seeded on the gel (in 200 μl of medium without FBS)
and 500 μl of complete medium was added into the
lower chamber of the transwell. Cells invaded through
transwell were stained after 24 h incubation. Five images
were photographed for each transwell under 100X mag-
nification. Cell numbers were counted and calculated.
Microarray analysis
Total RNA was incubated with DNase I at 37 °C for
15 min and subjected to microarray analysis of mRNA
expression delicately using the Human OneArray v6.1
from Phalanx Biotech (Taiwan). Standard selection cri-
teria to identify differentially expressed genes are log2
|Fold change| ≥ 1 and p < 0.05. Data were processed by
using DAVID bioinformatics Resources subjected to
KEGG pathway analysis.
Statistical analysis
Data are presented as the mean ± SD. Statistical analysis
between the control and the treatment groups were
compared using the Student’s t-test. A p value < 0.05 was
considered statistically significant. * represents p < 0.05,
** represent p < 0.01, and *** represent p < 0.001. Statis-
tical analysis was performed using StatView (version 5.0;
SAS Institute, Cary, NC).
Results
Morphology changed in invasive subclones of A253
The invasive HNSCC subclones were obtained using the
same method described as for an invasion assay. Cells
invaded through the membrane of transwell were col-
lected and cultured for another round of selection.
Numbers of selection were marked following the name
of cells. Parental A253 cultured in low (Fig. 1a) or high
density (Fig. 1b) showed mostly epithelia type appear-
ance and A253-3 (Fig. 1c) and A253-5 (Fig. 1d) showed
more spindle-like or mesenchymal type appearance (in-
dicated by arrows) under 100X magnificence. Figure 2
shows high-resolution pictures of A253-0 and A253-5 by
a FE-SEM. The structure of filopodia and lamellipodia
was varied advanced in A253-5, suggesting the better
mobility of A253-5 cell.
DNMT 3B protein expression was aberrant in HNSCC
cell lines. Notably, the invasive subclones of A253 and RPMI
2650 had higher expression of DNMT 3B (Fig. 3a) than that
of parental cells. In these four HNSCC cell lines, A253 and
RPMI2650 also showed the most difference of mobility be-
tween parental and filial cells. Moreover, EMT marker
genes: E-cadherin (E-cad) was downregulated; N-cadherin
(N-cad) and Vimentin were upregulated in A253-5 cell re-
vealed the occurrence of EMT (Fig. 3b). Stable clone of
knockdown DNMT 3B was achieved by transfection
siRNA against DNMT 3B into A253-5 and marked as
A253-5si. Q-PCR results showed the specificity of
siRNA (with no influence to DNMT 1 and DNMT 3A)
and the knockdown efficiency was around 60 %. Knock-
down of DNMT 3B resulted in cell morphology rever-
sion (Additional file 2: Figure S1A, B and C) and up-
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regulation of E-cad and down-regulation of N-cad and
Vimentin, suggesting DNMT 3B may lead to the inhib-
ition of EMT.
Knockdown of DNMT 3B could restore E-cadherin
expression by demethylation of promoter region
5′AZA was applied to inhibit DNMTs activity in A253
cells. The expression of E-cad was restored after 5′AZA
treatment in A253-5 suggested that down-regulation of
E-cad might be due to promoter methylation (Fig. 4a).
The 5′ region of E-cad was analyzed (−300 to +150) and
there were 33 CpG sites (Fig. 4b). The MS-PCR results
showed the methylated CpG sites in A253-5 and methyl-
ated amplicon cannot be detected in A253-5si (Fig. 4c).
The BGS results showed that less than 3 % of CpG sites
were methylated in parental cells and more than 70 %
were methylated in invasive subclone A253-5 (Fig. 4d).
These results indicated the knockdown of DNMT 3B
caused significantly demethylate of E-cad 5′ region.
Photograph of A253-5 cells treated with 5′AZA were
taken under 100X magnificence and the cell showed
mostly epithelia type appearance (Additional file 2: Figure
S1B and D).
Mir-29b mimic could downregulate DNMT 3B and inhibit
EMT
Interestingly, miRNA 29b was found downregulated in in-
vasive subclones of A253 cells and knockdown of DNMT
Fig. 1 Morphology changed and EMT-related transcription factors expression in invasive subpopulation of A253. Parental A253 (a with low density:
4 × 103cells per mm2 and b with high dansity: 1 × 104 cells per mm2) cells were photographed at 100 X magnificence. Invasive subpopulation of
A253-3 (c) and A253-5 (d) (with hight dansity: 1 × 104 cells per mm2) had more spindle-shape cells (indicated by arrows). e Three EMT-related
transcription factors (Snail, Slug, and Twist) were evaluated its mRNA expression by Q-PCR. Data was expressed as fold change to A253-0.
** indicated p < 0.01 and *** indicated p < 0.001 as compared with A253-0
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3B did not influence the miRNA 29b expression (Fig. 5a).
However, A253-5 transfected with miRNA 29b mimic
could not only inhibit DNMT 3B expression but also
reverse EMT marker genes expression (increase E-cad
and decrease N-cad and Vimentin expression; Fig. 4b).
Figure 5c and d show that downregulation of DNMT
3B through either small interfering RNA (A253-5si) or
miRNA 29b mimic (A253-5 Mir-29b), which could in-
hibit the migration and invasion of A253-5 in vitro.
Photograph of A253-5 cells transfected with miRNA
29b mimic were taken under 100X magnificence and the
cell showed mostly epithelia type appearance (Additional
file 2: Figure S1B and E).
mRNA enrichment analysis
A total of 707 genes (412 upregulated and 295 down regu-
lated) were identified with the differentially expression log2
|Fold change| ≥ 1 and p < 0.05 between A253-0 and A253-
5. For the clustering analysis, the first 250 genes with the
difference between the maximum and minimum intensity
values were selected (Additional file 3: Figure S2). The
canonical pathway analysis showed that top 5 pathways
(according to most significance in database) are involved in
invasive subclone A253-5 cells including arginine and
proline metabolism, general pathways in cancer, TGF-beta
signaling, focal adhesion and insulin signaling (Table 1).
Tables 2, 3 and 4 list individual genes overlapping with
three pathways including arginine and proline metabolism,
TGF-beta signaling, and focal adhesion, respectively. These
results indicated that possible genes or pathways are
involved in the induction of EMTand cell invasion.
Discussion
Accumulating evidence has pointed out the involvement of
the EMT in morphological changes from a cobblestone-like
of epithelial cells to a spindle-shaped mesenchymal cell
morphology [30, 31]. Using the methods descripted in this
study, we performed a process of invasion in vitro and ob-
tained the EMT cell with advanced mobility. The appear-
ance of invasive subclone of A253-5 shows advanced
structures of filopodia and lamellipodia. These protrusive
structures of cell are believed to enforce cells invasion
through extracellular matrix (ECM). The major organizer
of actin assembly in lamellipodia is the Arp2/3 complex
and other subunits (ArpC1 ~C4) [32]. The Arp2/3 com-
plex initiates the new actin filaments in lamellipodia and is
regulated by Scar/WAVE complex [33], which interact with
the small GTPase Rac1 [34, 35]. Filopodia are actin-
containing spurs, which are involved in cell migration and
controlled by numbers of proteins including fascin, diaph-
anous, and Mena/VASP. Fascin can bundle with actin and
form the filament networks to promote filopodia growth
Fig. 2 FE-SEM images of A253 cells. Parental A253 (a) and A253-5 (b) cells were examed under FE-SEM, upper panel show the cell appearance at
2000 X magnificence and lower panel show at 5500 X magnificence. Invasive A253-5 show the flourishing structure of filopodia and lamellipodia
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[36]. Of note the activity of actin bundling is regulated by
small GTPases Rac and Cdc42 [37, 38]. Thereby, the actin
dynamics in filopodia and lamellipodia is implicated in the
process of cancer metastasis and invasion [32].
DNMTs are enzymes responsible for DNA methylation
pattern in cells. However, aberrant DNA methylation of
tumor suppressor genes is validated as a frequent mo-
lecular event in human carcinomas [20]. Aberrant
DNMT 3B expression is associated with various cancers
including breast cancer [39], colorectal cancer [40, 41],
stomach cancer [40, 41], and lung cancer [42]. It is
also suggested that DNMT 3B is required for tumor
development [43] and promotes tumorigenesis by
hypermethylation of tumor suppresser gene such as
Sfrp family [44]. Moreover, the transcription variants
of DNMT 3B have shown its role in tumor progres-
sion [45]. There are seven aberrant transcripts from
unconventional pre-mRNA splicing found in lung
cancer. One of the transcription variant, DNMT 3B7,
is demonstrated by the effect on E-cad methylation
and 2-fold decrease in E-cad expression paralleled
[46]. DNMT3B7 has recently shown its promoting
role in tumor progression to a more invasive pheno-
type in breast cancer cell lines [47].
Previous evidence has shown that the down regulation
of mir-29b is found in non-small cell lung cancer [48],
glioblastoma [49], prostate cancer [50], ovarian cancer
[51], and HNSCC [52]. Several lines of cellular function
in mir-29b are proposed such as promotion of apoptosis,
suppression of tumor invasion, and regulation of EMT.
Firstly, miR-29 family can trigger cell apoptosis by dir-
ectly binding to Mcl-1(anti-apoptotic gene) and pre-
venting expression of Mcl-1 [53]. Enhancements of the
miR-29b expression may reduce Mcl-1 protein and
increase the cytotoxicity induced by tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) [54].
In acute myeloid leukemia (AML) cell, ectopic transfec-
tion of synthetic miR-29b can up-regulate the pro-
apoptotic genes, such as BIM (BCL2L11) and the tumor
suppressor programmed cell death-4 (PDCD4) [55].
Fig. 3 Aberrant expression of DNMT 3B in HNSCC cell lines and knockdown of DNMT 3B in A253-5 reversed EMT marker genes. a DNMT 3B
protein expression in HNSCC cell lines and its invasive subpopulations. b DNMTs and EMT marker genes protein expression in A253 and its
invasive subpopulations (A253-3, A253-5) and A253-5 transfected with siRNA against DNMT 3B (A253-5 si). ** indicated p < 0.01 and *** indicated
p < 0.001 as compared with A253-0. ### indicated p < 0.001 as compared with A253-5si
Chen et al. BMC Cancer  (2016) 16:431 Page 6 of 13
Secondly, the inhibition of miR-29b causes the increasing
expression of DNA binding 1 (ID1) and MMP9, which
lead to tumor cell invasion [56]. MiR-29 family has also
demonstrated its tumor suppressor role by targeting lam-
inin γ2 (LAMC2) and α6 integrin (ITGA6) resulting in
the inhibition of cell migration and invasion in HNSCC
cell line (SAS and FaDu) [52]. Thirdly, overexpression of
miR-29 may block EMT by targeting ADAM12, which is
highly associated with invasion and EMT in breast cancer
[57]. Moreover, a transcription factor GATA3 is found to
promote miR-29b expression and suppress metastasis
of breast cancer by inducing miR-29b. MiR-29b may
target numbers of pro-metastatic regulators associated
with angiogenesis, collagen remodeling and proteolysis;
thereby, altering the tumor microenvironment [58, 59].
Furthermore, miR-29 family is reported its involvement
in the downregulation of DNMT 3A and 3B in lung
cancer cell line and AML, suggesting that miR-29b may
Fig. 4 Involvement of DNA methylation in E-cadherin 5′ region. a Demethylation agent 5′AZA could restored E-cadherin expression on A253-5
cells. b Illustration of CpG islands distribution on 5′ region of E-cadherin. c Methylation specific PCR of E-cadherin in A253 cells. M indicated
methylated amplicon and U indicated unmethylated amplicon. MSS1, positive control; WBC: normal human white blood cell for negitive control.
d Bissulfite sequence of E-cadherin in A253 cells reveal that knockdown of DNMT 3B could result in demethylation of 5′ region of E-cadherin.
*** indicated p < 0.001 as compared with A253-0 and ### indicated p < 0.001 as compared with A253-5
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Fig. 5 MiRNA 29b mimic targeted DNMT 3B and reversed EMT. a Q-PCR examination of miRNA 29b expression in A253 cells. * indicated
p < 0.05 and ** indicated p < 0.01 as compared with A253-0. # indicated that there were no statistically significant between A253-5 and A253-5si
(Knockdown of DNMT 3B). b Transfection of miRNA 29b mimic could downregulate DNMT 3B and reverse EMT marker genes in A253-5.
c, d Migration and invasion assay. Knockdown DNMT 3B by small interfering RNA or mir-29b mimic could inhibit cell mobility. * indicated
p < 0.05, ** indicated p < 0.01 and *** indicated p < 0.001 as compared with A253-5
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alter the methylation status of tumor-suppressor genes
resulting in the inhibition of carcinogenic process [48, 60].
According the mRNA enrichment analysis, we reported
the most involvement of five pathways in invasive A253
cell (Table 1). We focus on three of pathways including
arginine and proline metabolism, TGF-beta and focal ad-
hesion with discussion. Proline dehydrogenase (PRODH)
is a mitochondrial enzyme transferring the electrons from
proline and producing pyrroline-5-carboxylate (P5C). A
hypothetical proline metabolic timeline in cancer was also
proposed [61]. During the early stage of cancer pro-
gression like chronic inflammation and DNA damage,
PRODH could be induced by PPARγ [62] and P53 [63],
respectively. PRODH was reported as a tumor suppressor
gene in 2009 [64]. Using the Tet-off system, the growth of
xenograft colorectal tumor is suppressed by expressing
PRODH in immune-deficient mice. The immunohis-
tochemical (IHC) assay was also applied to examine the
expression of PRODH in digestive tract and renal tumor.
Comparing to the normal tissue, 78 and 85 % of the
tumors (digestive tract and renal tumor, respectively) have
markedly decreased or undetectable PRODH expression
[64, 65]. From our results, PRODH was found 2.72 fold
down regulated in invasive A253-5 cell.
TGF-beta displays a distinct role in tumor develop-
ment [66]. In the initial stage of tumor progression,
TGF-beta may induce growth arrest and apoptosis onto
cancer cells. However, TGF-beta plays as a tumor pro-
moter role due to the induction of EMT and increasing
of invasiveness in late stages [67]. Interestingly, SMAD4
is the key mediator of TGF-beta signaling [68] and is
found 3.67 fold down regulated in invasive A253-5 cell.
Previous studies have shown that a loss of SMAD4
expression by deletion in mice model might trigger
spontaneous HNC, mammary gland tumors, and skin
SCC development [69–71]. The genome wide analysis of
HNSCC also showed the frequent deletion of SMAD4
[72] and heterozygous loss of Smad4 in HNSCC [73].
The reduction of SMAD4 is found in tumors, 67 % of
the adjacent non-tumor tissues from HNSCC patients
also show more than 50 % SMAD4 reduction [71].
These results imply that the down regulation of SMAD4
might be an early event in HNSCC progression. A recent
study shows that TGF-beta could induce EMT and
change DNA methylation status by upregulated DNMTs
in ovarian cancer cells [74]. Considering the downregula-
tion of SMAD4, SMAD6, and the inhibitor of DNA bind-
ing family (ID1 ~ ID4), the involvement of TGF-beta in
our model system may be through SMAD-independent or
non-SMAD signaling [75]. Par6 may be phosphorylated by
activated TGF-beta receptor II and regulate Rho GTPase
activity resulting in actin polymerization and negatively
regulation of tight junction assembly during the EMT
[76]. Moreover, the ubiquitin ligase TRAF6 may be acti-
vated by TGF-beta receptor I following the activation of
JNK and p38 MAP kinases leading to EMT [77].
Most of genes identified in the focal adhesion pathway are
upregulated and indicated a positive regulation of mobility
in invasive A253-5 cell. Fibronectin (FN) is a well-defined
mesenchymal marker [10] and is found 12 fold upregulated
in invasive A253-5 cell. FN is involved in many cellular func-
tions including cell migration, differentiation, wound heal-
ing, and carcinoma development [78–80]. During the EMT,
epithelia cell loss of the cell-cell contact and switch to cell-
Table 1 Top 5 most enriched pathways of genes differentially
expressed in invasive A253 cells according to KEGG pathway
enrichment analysis
KEGG pathways # of genes in
overlap/geneset
P value
Arginine and proline metabolism 10/54 1.25E-09
Pathways in cancer 21/328 1.48E-09
TGF-beta signaling pathway 10/86 1.29E-07
Focal adhesion 14/201 2.89E-07
Insulin signaling pathway 11/137 1.35E-06
Table 2 Differentially expressed genes overlap in KEGG arginine and proline metabolism pathway
Gene_symbol Description Log2 Ratio (A253-5/A253-0) P value
NOS3 nitric oxide synthase 3 2.7864 1.98847E-18
NOS1 nitric oxide synthase 1 −1.0344 0.001156601
ALDH2 aldehyde dehydrogenase 2 family −2.2530 1.27408E-16
GLS2 glutaminase 2 −1.1956 0.000792972
GAMT guanidinoacetate N-methyltransferase −1.5676 3.38943E-10
GATM glycine amidinotransferase 1.2157 0.048297875
ODC1 ornithine decarboxylase 1 1.1353 1.1552E-08
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I −1.0132 0.000552165
PRODH proline dehydrogenase (oxidase) 1 −1.3810 0.00044575
SAT1 spermidine/spermine N1-acetyltransferase 1 1.0905 0.000181734
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ECM interaction implicit the possibility of EMT promoting
role of FN. Cultured breast cancer cells with FN induced
EMT through Scr and ERK/MAP kinases pathways support
a high level of FN, which was detected in the breast tumor
sections [81]. Collagen type IV alpha 1 (COL4A1), another
mesenchymal marker gene [18] was identified with 4.42 fold
upregulated in invasive A253-5 cell. A recent study showed
that the knockdown of COL4A1 could reduce mouse mel-
anoma cell motility and decrease lung metastasis in vivo
[82]. Tenascin C (TNC) is a target gene of TGF-beta [83]
and is found 3.04 fold upregulated in invasive A253-5 cell.
TNC is an expression exerted as the invasive edge of breast
tumor and serves as a prognostic marker for local and dis-
tant recurrence [84]. TNC is also highly expressed in the
microenvironment of most solid tumors by fibroblast cells
[85] as a pro-invasive signal leading to cell invasion through
activation of RhoA and Rac [86]. Moreover, co-expression of
TNC and vimentin might induce mesenchymal-like pheno-
type in breast cancer cell [87].
Conclusion
Here we report the involvement of DNMT 3B in the
induction of EMT of HNSCC cell lines. The downregula-
tion of DNMT 3B by miR-29b mimic may reverse EMT
and inhibit cell migration and invasion. Gene expression
profile of invasive HNSCC is also presented. Using a bio-
informatics tool, we are able to identify various genes that
participated in metabolism and cancer related pathways,
which may be involved in HNSCC metastasis. Although
these findings require further experimental validations,
follow-up research could find new molecules that
could serve as prognostic factors or therapeutic targets
for invasive HNSCC.
Table 3 Differentially expressed genes overlap in KEGG TGF-beta signaling pathway
Gene_symbol Description Log2 Ratio (A253-5/A253-0) P value
TGFB2 transforming growth factor, beta 2 1.4825 1.26645E-05
SMAD4 SMAD family member 4 −1.8344 7.44456E-12
THBS1 thrombospondin 1 1.0290 0.000135356
BMP7 bone morphogenetic protein 7 −1.0015 1.23496E-05
SMAD6 SMAD family member 6 −1.3877 2.88563E-05
FST follistatin 1.9942 3.77471E-09
ID1 inhibitor of DNA binding 1 −2.3048 3.76822E-16
ID2 inhibitor of DNA binding 2 −2.7118 5.48439E-12
ID3 inhibitor of DNA binding 3 −2.5933 2.77865E-16
ID4 inhibitor of DNA binding 4 −1.6108 2.7105E-06
Table 4 Differentially expressed genes overlap in KEGG focal adhesion pathway
Gene_symbol Description Log2 Ratio (A253-5/A253-0) P value
MAPK10 mitogen-activated protein kinase 10 −1.1440 0.000264947
AKT1 v-akt murine thymoma viral oncogene homolog 1 1.1076 0.014492851
PDGFB platelet-derived growth factor beta polypeptide 1.0834 6.23066E-05
BIRC3 baculoviral IAP repeat containing 3 1.0176 0.001517394
PGF placental growth factor −1.0496 0.025969431
COL4A1 collagen, type IV, alpha 1 2.1236 1.58011E-20
FN1 fibronectin 1 3.6490 3.35978E-24
THBS1 thrombospondin 1 1.0290 0.000135356
FLT1 fms-related tyrosine kinase 1 1.2325 0.025381832
RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 1.7221 1.11117E-05
CCND2 cyclin D2 2.3619 8.02038E-19
COL5A2 collagen, type V, alpha 2 1.2806 0.030736616
TNC tenascin C 1.6496 9.83873E-07
PARVA parvin, alpha 1.2195 9.20291E-07
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Additional files
Additional file 1: Table S1. Primers used in this study. Primers list for
MS-PCR, MSG and Q-PCR. (DOCX 14 kb)
Additional file 2: Figure S1. Morphology changed of various
treatments of A253 cells. A253-0 cell (A), A253-5 (B), A253-5si (C), A253-5
treated with 5′AZA (D) and A253-5 transfected with miRNA29b mimic (E).
Photographs were taken at 100 X magnificence and mesenchymal type
cells were indicated by arrows. (DOCX 430 kb)
Additional file 3: Figure S2. Clustering analysis of difference genes
expression between A253-0 and A253-5. A total of 250 genes with the
difference between the maximum and minimum intensity values were
clustered. (JPG 172 kb)
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